Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection

NCT05466240 is registered in ClinicalTrials.gov with Atea Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05466240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05466240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection
Lead sponsor
Atea Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 29, 2022
Completion date
January 19, 2023
Enrollment
21 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever